Adam J Shapiro1, Stephanie D Davis2, Thomas Ferkol3, Sharon D Dell4, Margaret Rosenfeld5, Kenneth N Olivier6, Scott D Sagel7, Carlos Milla8, Maimoona A Zariwala9, Whitney Wolf10, Johnny L Carson11, Milan J Hazucha10, Kimberlie Burns10, Blair Robinson11, Michael R Knowles10, Margaret W Leigh11. 1. From the Department of Pediatrics, Montreal Children's Hospital, McGill University, Montreal, QC, Canada. Electronic address: adam.shapiro@muhc.mcgill.ca. 2. Department of Pediatrics, Riley Hospital for Children, Indiana University, Indianapolis, IN. 3. Department of Pediatrics, Washington University School of Medicine, St. Louis, MO. 4. Department of Pediatrics, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada. 5. Department of Pediatrics, Seattle Children's Hospital and University of Washington, Seattle, WA. 6. National Institute of Allergy and Infectious Diseases, Bethesda, MD. 7. Department of Pediatrics, Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, CO. 8. Department of Pediatrics, Stanford University, Palo Alto, CA. 9. Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC. 10. Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC. 11. Department of Pediatrics, University of North Carolina School of Medicine, on behalf of the Genetic Disorders of Mucociliary Clearance Consortium, Chapel Hill, NC.
Abstract
BACKGROUND: Motile cilia dysfunction causes primary ciliary dyskinesia (PCD), situs inversus totalis (SI), and a spectrum of laterality defects, yet the prevalence of laterality defects other than SI in PCD has not been prospectively studied. METHODS: In this prospective study, participants with suspected PCD were referred to our multisite consortium. We measured nasal nitric oxide (nNO) level, examined cilia with electron microscopy, and analyzed PCD-causing gene mutations. Situs was classified as (1) situs solitus (SS), (2) SI, or (3) situs ambiguus (SA), including heterotaxy. Participants with hallmark electron microscopic defects, biallelic gene mutations, or both were considered to have classic PCD. RESULTS: Of 767 participants (median age, 8.1 years, range, 0.1-58 years), classic PCD was defined in 305, including 143 (46.9%), 125 (41.0%), and 37 (12.1%) with SS, SI, and SA, respectively. A spectrum of laterality defects was identified with classic PCD, including 2.6% and 2.3% with SA plus complex or simple cardiac defects, respectively; 4.6% with SA but no cardiac defect; and 2.6% with an isolated possible laterality defect. Participants with SA and classic PCD had a higher prevalence of PCD-associated respiratory symptoms vs SA control participants (year-round wet cough, P < .001; year-round nasal congestion, P = .015; neonatal respiratory distress, P = .009; digital clubbing, P = .021) and lower nNO levels (median, 12 nL/min vs 252 nL/min; P < .001). CONCLUSIONS: At least 12.1% of patients with classic PCD have SA and laterality defects ranging from classic heterotaxy to subtle laterality defects. Specific clinical features of PCD and low nNO levels help to identify PCD in patients with laterality defects. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00323167; URL: www.clinicaltrials.gov.
BACKGROUND:Motile cilia dysfunction causes primary ciliary dyskinesia (PCD), situs inversus totalis (SI), and a spectrum of laterality defects, yet the prevalence of laterality defects other than SI in PCD has not been prospectively studied. METHODS: In this prospective study, participants with suspected PCD were referred to our multisite consortium. We measured nasal nitric oxide (nNO) level, examined cilia with electron microscopy, and analyzed PCD-causing gene mutations. Situs was classified as (1) situs solitus (SS), (2) SI, or (3) situs ambiguus (SA), including heterotaxy. Participants with hallmark electron microscopic defects, biallelic gene mutations, or both were considered to have classic PCD. RESULTS: Of 767 participants (median age, 8.1 years, range, 0.1-58 years), classic PCD was defined in 305, including 143 (46.9%), 125 (41.0%), and 37 (12.1%) with SS, SI, and SA, respectively. A spectrum of laterality defects was identified with classic PCD, including 2.6% and 2.3% with SA plus complex or simple cardiac defects, respectively; 4.6% with SA but no cardiac defect; and 2.6% with an isolated possible laterality defect. Participants with SA and classic PCD had a higher prevalence of PCD-associated respiratory symptoms vs SA control participants (year-round wet cough, P < .001; year-round nasal congestion, P = .015; neonatal respiratory distress, P = .009; digital clubbing, P = .021) and lower nNO levels (median, 12 nL/min vs 252 nL/min; P < .001). CONCLUSIONS: At least 12.1% of patients with classic PCD have SA and laterality defects ranging from classic heterotaxy to subtle laterality defects. Specific clinical features of PCD and low nNO levels help to identify PCD in patients with laterality defects. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00323167; URL: www.clinicaltrials.gov.
Authors: Jeffrey P Jacobs; Robert H Anderson; Paul M Weinberg; Henry L Walters; Christo I Tchervenkov; Danny Del Duca; Rodney C G Franklin; Vera D Aiello; Marie J Béland; Steven D Colan; J William Gaynor; Otto N Krogmann; Hiromi Kurosawa; Bohdan Maruszewski; Giovanni Stellin; Martin J Elliott Journal: Cardiol Young Date: 2007-09 Impact factor: 1.093
Authors: Nader Nakhleh; Richard Francis; Rachel A Giese; Xin Tian; You Li; Maimoona A Zariwala; Hisato Yagi; Omar Khalifa; Safina Kureshi; Bishwanath Chatterjee; Steven L Sabol; Matthew Swisher; Patricia S Connelly; Mathew P Daniels; Ashok Srinivasan; Karen Kuehl; Nadav Kravitz; Kimberlie Burns; Iman Sami; Heymut Omran; Michael Barmada; Kenneth Olivier; Kunal K Chawla; Margaret Leigh; Richard Jonas; Michael Knowles; Linda Leatherbury; Cecilia W Lo Journal: Circulation Date: 2012-04-12 Impact factor: 29.690
Authors: Mary Ella Pierpont; Martina Brueckner; Wendy K Chung; Vidu Garg; Ronald V Lacro; Amy L McGuire; Seema Mital; James R Priest; William T Pu; Amy Roberts; Stephanie M Ware; Bruce D Gelb; Mark W Russell Journal: Circulation Date: 2018-11-20 Impact factor: 29.690
Authors: Adam J Shapiro; Karen E Weck; Kay C Chao; Margaret Rosenfeld; Anders O H Nygren; Michael R Knowles; Margaret W Leigh; Maimoona A Zariwala Journal: J Pediatr Date: 2014-07-25 Impact factor: 4.406
Authors: Stephanie D Davis; Thomas W Ferkol; Margaret Rosenfeld; Hye-Seung Lee; Sharon D Dell; Scott D Sagel; Carlos Milla; Maimoona A Zariwala; Jessica E Pittman; Adam J Shapiro; Johnny L Carson; Jeffrey P Krischer; Milan J Hazucha; Matthew L Cooper; Michael R Knowles; Margaret W Leigh Journal: Am J Respir Crit Care Med Date: 2015-02-01 Impact factor: 21.405
Authors: Weining Yin; Alessandra Livraghi-Butrico; Patrick R Sears; Troy D Rogers; Kimberlie A Burns; Barbara R Grubb; Lawrence E Ostrowski Journal: Am J Respir Cell Mol Biol Date: 2019-09 Impact factor: 6.914
Authors: Adam J Shapiro; Sue Tolleson-Rinehart; Maimoona A Zariwala; Michael R Knowles; Margaret W Leigh Journal: Cardiol Young Date: 2014-06-06 Impact factor: 1.093
Authors: Adam J Shapiro; Sharon D Dell; Benjamin Gaston; Michael O'Connor; Nadzeya Marozkina; Michele Manion; Milan J Hazucha; Margaret W Leigh Journal: Ann Am Thorac Soc Date: 2020-02
Authors: Adam J Shapiro; Stephanie D Davis; Deepika Polineni; Michele Manion; Margaret Rosenfeld; Sharon D Dell; Mark A Chilvers; Thomas W Ferkol; Maimoona A Zariwala; Scott D Sagel; Maureen Josephson; Lucy Morgan; Ozge Yilmaz; Kenneth N Olivier; Carlos Milla; Jessica E Pittman; M Leigh Anne Daniels; Marcus Herbert Jones; Ibrahim A Janahi; Stephanie M Ware; Sam J Daniel; Matthew L Cooper; Lawrence M Nogee; Billy Anton; Tori Eastvold; Lynn Ehrne; Elena Guadagno; Michael R Knowles; Margaret W Leigh; Valery Lavergne Journal: Am J Respir Crit Care Med Date: 2018-06-15 Impact factor: 21.405